ABIVAX to present at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464

Paris, France January 21st 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing novel antiviral therapies for diseases like HIV/AIDS and chronic Hepatitis B (CHB), today announced the acceptance of the abstract  "Early Evidence of Antiviral Activity & Safety of ABX464 in HIV Treatment Naive Patients," as a late-breaking news presentation by the prestigious Conference on Retroviruses and Opportunistic Infections (CROI), t0 be held February 22-25, 2016 in Boston, Massachusetts, at the Hynes Convention Center. 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41